Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Waste Management, Inc. — how do they compare? Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B), while Waste Management, Inc. trades at $219.32 (market cap $86.24B). The key difference: Waste Management, Inc. is far larger — about 17.2× Travere Therapeutics Inc. Common Stock's market cap, and Waste Management, Inc. pays a 1.75% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Waste Management, Inc. for 131 Days on average.
| TVTX | WM | |
|---|---|---|
Market Cap | $5.02B | $86.24B |
Volume | 2,060,842 | 1,938,815 |
Sector | Health | Industrials |
52-Week High | $67.52 | $246.51 |
52-Week Low | $26.79 | $196.77 |
Typical Hold Time | 0 Days | 131 Days |
Enterprise Value | $5.15B | $109.04B |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Waste Management (WM) trades at $211.83, up 0.33% with a bullish technical signal despite mixed moving averages. The company demonstrates strong fundamentals with $25.2B revenue, 11.12% net margin, and robust cash flow generation. Recent earnings show two beats out of three quarters, with Q3 2026 results pending. Analyst consensus is strongly positive with 54% buy ratings and no sell recommendations.
WM presents a compelling investment case with consistent revenue growth, strong profitability metrics, and defensive business model. However, elevated valuation multiples (P/E 29.96) and rising debt levels warrant caution. The stock offers stability through economic cycles but faces margin pressure from cost inflation and competitive threats in waste management services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
